Experts to Examine the Clinical Impact of Recent FDA Decisions and Cutting-Edge Trial Data at the Cardiometabolic Health Congress
BOSTON, Oct. 12, 2012 /PRNewswire/ -- The approval of two new weight-loss medications, cutting-edge data on novel hypertension therapies and the approval of a novel prescription omega-3 formulation for triglyceride lowering will be among the important new developments discussed at one of the most highly anticipated Cardiometabolic Health Congress (CMHC) sessions: "Late-Breaking Clinical Trials & FDA Update: How Will the Latest Data Impact Clinical Practice?" The session takes place on Friday, Oct. 12, 2012, from 10:30 am to 11:45 am.
Each year, the CMHC chairpersons and other noted experts in the field of cardiometabolic health plan this session in order to help clinicians understand how important clinical trials and FDA actions they may have heard about in the news will affect them and their patients.
Following are the featured speakers and specific items slated for discussion so far. Of course, the topics may change as new FDA actions and clinical trial results emerge.
- Keith Ferdinand, MD, will present and analyze the implications of the most recent clinical trial data evaluating renal sympathetic denervation and baroreflex activation therapy for treating resistant hypertension.
- Christie Ballantyne, MD, will discuss the approval of AMR101, a novel prescription omega-3 formulation for triglyceride reduction, as well as give an update on the status of experimental and emerging lipid-lowering drugs, including ApoB, PCSK9 and MTP inhibitors.
- Robert Eckel, MD, will discuss the recent FDA approval of lorcaserin and phentermine/topiramate for weight loss, with the aim of helping clinicians understand the indications and appropriate dosing of these drugs. He will also evaluate the latest data on the impact of bariatric surgery on weight loss and Type 2 diabetes.
- Jay Skyler, MD, will examine the most recent data on cancer risk associated with pioglitazone, insulin, GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of diabetes. He will also provide perspective on the recently reported results of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial.
- Stephen Wiviott, MD, will address recent guideline changes in the field of acute coronary syndrome (ACS) and thrombosis management, including guideline updates for ticagrelor and for aspirin therapy in secondary acute coronary syndrome prevention. He will also discuss the status of novel and emerging antithrombotic therapies under FDA review.
"Every year this session gets more exciting, with the impact on practice always timely," said Dr. Eckel.
The 7th Annual CMHC, featuring 64 world-renowned expert faculty, 15 scientific sessions, 16 corporate-supported and corporate-sponsored symposia, and approximately 30 CME credit hours, will convene Oct. 10–13, 2012, in Boston. The event is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including obesity, Type 2 diabetes, cardiovascular disease, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.
SOURCE Cardiometabolic Health Congress